AI Oral Cyclic Peptide Scaffold Hopping Service
CD ComputaBio's AI Oral Cyclic Peptide Scaffold Hopping Service constructs an intelligent pathway from existing bioactive peptides to novel, patentable therapeutic candidates. In drug discovery, scaffold hopping — the migration of bioactivity from one chemical framework to another — is a critical strategy for overcoming intellectual property barriers, improving pharmacokinetic properties, and accessing novel chemical space. However, traditional scaffold hopping in peptide space is severely constrained by the limited availability of diverse, drug-like scaffolds. Our platform leverages Generative AI and Deep Learning to systematically redesign bioactive linear or cyclic peptides onto entirely new macrocyclic architectures, preserving target affinity while dramatically improving oral bioavailability, metabolic stability, and synthetic accessibility. This "Structure-to-Scaffold" transformation enables rapid escape from crowded IP landscapes and optimization of lead compounds with suboptimal drug-like properties.
Figure 1. AI-Driven Scaffold Hopping from Linear Peptides to Oral Macrocycles.
Introduction to AI Oral Cyclic Peptide Scaffold Hopping Service
In modern medicinal chemistry, scaffold hopping represents one of the most powerful strategies for lead optimization and IP diversification. For peptide therapeutics, this challenge is particularly acute — natural bioactive peptides often suffer from poor proteolytic stability, limited oral absorption, and complex synthesis, yet medicinal chemists lack systematic methods to migrate bioactivity to superior macrocyclic frameworks. Recent advances in generative AI, exemplified by platforms like Unnatural Products' AI-driven macrocycle design , demonstrate the feasibility of de novo scaffold generation with predictable properties.
Our AI Oral Cyclic Peptide Scaffold Hopping Service addresses this gap by providing a systematic, AI-powered methodology for peptide scaffold migration. Trained on extensive datasets of peptide bioactivity, macrocycle structures, and structure-activity relationships, our system employs:
- Pharmacophore extraction: AI identification of essential binding elements and bioactive conformations from source peptides.
- Scaffold generation: De novo design of novel macrocyclic architectures that maintain pharmacophore geometry while improving drug-likeness.
- Property optimization: Simultaneous optimization for oral bioavailability, metabolic stability, and synthetic tractability.
- IP landscape analysis: Computational assessment of structural novelty and patent freedom.
This enables the transformation of promising but undevelopable peptide hits into patentable, orally bioavailable drug candidates with superior pharmaceutical properties.
Our Services
Powered by our proprietary AI scaffold hopping engine, we provide comprehensive peptide-to-macrocycle transformation services:
Bioactive Peptide Analysis & Pharmacophore Mapping
AI-powered decomposition of source peptides into essential pharmacophore elements — identifying critical residues, spatial arrangements, and conformational constraints required for target engagement. Our system distinguishes between "must-have" features and modifiable regions to guide scaffold design.
Novel Macrocyclic Scaffold Generation
Generative AI models create diverse, chemically novel macrocyclic scaffolds that precisely present identified pharmacophores in bioactive conformations. The system explores unconventional cyclization strategies, non-natural amino acids, and synthetic building blocks to generate patentable architectures distinct from starting structures.
Oral Bioavailability Engineering
Systematic optimization of scaffold physicochemical properties for oral delivery — including control of molecular weight, polar surface area, and lipophilicity. Our AI predicts human intestinal permeability and first-pass metabolism, prioritizing scaffolds with >20% predicted oral bioavailability.
Synthetic Accessibility Scoring
AI assessment of synthetic feasibility for each proposed scaffold, considering solid-phase peptide synthesis compatibility, cyclization efficiency, and commercial availability of building blocks. The system favors scaffolds amenable to rapid analog synthesis and scale-up.
IP Novelty & Freedom-to-Operate Analysis
Computational comparison of AI-generated scaffolds against patent databases and known bioactive peptides. We provide structural novelty scores, patent landscape reports, and guidance on claimable chemical space to ensure freedom-to-operate and strong IP positions.
Activity Preservation Validation
Molecular modeling and AI predictions confirming that scaffold-hopped candidates maintain target binding affinity and functional activity. We design focused libraries for experimental validation, prioritizing candidates with predicted equipotency or improved activity versus starting peptides.
Application Scenarios
AI Oral Cyclic Peptide Scaffold Hopping Services enable diverse strategic applications across the drug discovery pipeline:
Figure 2. Application Scenarios of AI Oral Cyclic Peptide Scaffold Hopping.
Patent Escape and Lifecycle Management: Transform proprietary or competitor peptides onto novel macrocyclic scaffolds to circumvent composition-of-matter patents, extend product lifecycles, or establish differentiated IP positions. Our AI identifies scaffold hops that maintain activity while achieving structural novelty sufficient for patentability.
Natural Product Peptide Optimization: Migrate bioactive peptides from natural sources (e.g., venoms, antimicrobial peptides, hormones) onto synthetic macrocyclic scaffolds with improved drug-like properties. Applications include converting toxic or unstable natural peptides into safe, orally deliverable therapeutics.
Peptide Drug Generic Differentiation: For companies developing peptide generics or biosimilars, scaffold hopping provides pathways to differentiated products with improved formulations, dosing regimens, or safety profiles—enabling competitive positioning beyond simple replication.
Fragment-to-Macrocycle Evolution: Starting from small peptide fragments identified in fragment-based screening, our AI designs optimal macrocyclic scaffolds that link and orient fragments for high-affinity target engagement — creating novel chemical matter from weak starting points.
Process of AI Oral Cyclic Peptide Scaffold Hopping
Our scaffold hopping workflow ensures systematic transformation from source peptides to optimized macrocycles:

Source Peptide Analysis & Pharmacophore Extraction
Clients provide bioactive peptide sequences, structures, or patent references. Our AI system performs conformational analysis, identifies critical binding residues through alanine scanning prediction, and extracts 3D pharmacophore models—establishing design constraints for scaffold migration.

De Novo Scaffold Generation & Pharmacophore Matching
Generative AI models create thousands of novel macrocyclic scaffolds, evaluating each for pharmacophore fidelity, conformational pre-organization, and structural novelty. The system prioritizes scaffolds that maintain bioactive conformations while maximizing distance from starting structures.

Property Optimization & IP Assessment
Multi-parameter AI optimization for oral bioavailability, metabolic stability, and synthetic accessibility. Parallel computational patent searching assesses novelty and freedom-to-operate, filtering candidates to those with strong IP positions and developable properties.

Experimental Validation & Iterative Refinement
Synthesis of top-ranked scaffold-hopped candidates and experimental validation of target engagement, metabolic stability, and oral pharmacokinetics. AI models iteratively refine based on experimental data, converging on optimal candidates for development.
Our Advantages
Systematic Escape from IP Constraints
Traditional scaffold hopping relies on serendipitous discovery or limited chemical intuition. Our AI systematically explores vast chemical space, identifying scaffold migrations that achieve both activity preservation and structural novelty sufficient for patentability. We routinely achieve Tanimoto similarity scores <0.3 to starting peptides while maintaining bioactivity.
Simultaneous Multi-Parameter Optimization
Unlike sequential optimization approaches that improve one property at the expense of others, our AI performs true multi-objective optimization — simultaneously enhancing oral bioavailability, metabolic stability, synthetic accessibility, and target affinity. This identifies "win-win" scaffold hops invisible to traditional methods.
Rapid Exploration of Unconventional Scaffolds
Our generative models explore scaffold types beyond conventional medicinal chemistry intuition — including exotic cyclization topologies, non-proteinogenic amino acids, and hybrid peptide-small molecule architectures. This accesses chemical space poorly represented in existing compound libraries and patent databases.
Frequently Asked Questions
We employ multiple validation layers: (1) pharmacophore matching ensuring 3D arrangement of critical functional groups; (2) molecular docking and dynamics simulations confirming target binding mode preservation; (3) AI activity prediction models trained on scaffold hop examples; and (4) design of focused validation libraries to empirically confirm activity retention. Typical scaffold hops achieve 70-90% preservation of starting peptide affinity.
Absolutely. Scaffold hopping is not merely about IP avoidance — it's an opportunity to systematically optimize drug-like properties. Common improvements include: 10-100× enhanced metabolic stability, 5-50× improved membrane permeability, simplified synthesis (fewer steps, higher yields), and reduced immunogenicity risk. We design scaffold hops specifically to address liabilities in starting structures.
Our IP analysis includes: (1) structural similarity searching against patent databases and literature; (2) assessment of obviousness based on structural distance from prior art; (3) identification of claimable chemical space around AI-generated scaffolds; and (4) guidance on patent filing strategy. We provide FTO opinions and recommend structural modifications to ensure strong, defensible IP positions.
Connect with Us Anytime!
The future of peptide drug discovery lies in intelligent navigation of chemical space — transforming promising bioactive sequences into patentable, developable therapeutic candidates. CD ComputaBio is committed to eliminating the barriers between natural bioactivity and pharmaceutical excellence through AI-powered scaffold engineering.
Experience the power of AI-driven scaffold hopping. to learn how our AI Oral Cyclic Peptide Scaffold Hopping Service can unlock novel chemical space, secure IP freedom, and accelerate your peptide therapeutics from concept to clinic!